Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pfizer's Avelumab Makes Its Debut, In Rare Form Of Skin Cancer

Executive Summary

Pfizer got Bavencio to market by focusing on an unmet need, but the PD-L1 inhibitor is still a few years behind, competing with other checkpoint inhibitors over more valuable indications.

You may also be interested in...



Keeping Track Of The US FDA's Final Approvals Of 2018

A roundup of the US FDA's drug approvals in the final weeks of 2018.

Merck KGAA/Pfizer's Anti-PD-L1 Bavencio Loses An Opportunity In Ovarian Cancer

PD-1/L1 inhibitors are eagerly awaited in ovarian cancer, but the combination of Bavencio with chemotherapy doesn't work well in platinum-resistant disease.

Deal Watch: Pfizer Offloads Troubled ADHD Products To Manufacturer Tris

Tris acquires Pfizer subsidiary Nextwave, which developed pair of ADHD drugs using Tris delivery technology. Lilly gets oral CGRP candidate from Chugai, while Dova signs US co-promotion partner for Doptelet.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC098447

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel